Optinose US, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.6M
Doctors Paid
14,798
Transactions
106,650
2024 Total
$1.4M
Payment Breakdown by Category
Research$6.1M (38.9%)
Food & Beverage$2.2M (14.4%)
Consulting$1.6M (10.3%)
Travel$819,514 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.1M | 987 | 38.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.2M | 2,599 | 27.2% |
| Food and Beverage | $2.2M | 99,573 | 14.4% |
| Consulting Fee | $1.6M | 774 | 10.3% |
| Travel and Lodging | $819,514 | 2,456 | 5.3% |
| Honoraria | $447,300 | 211 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $117,585 | 38 | 0.8% |
| Education | $32,000 | 8 | 0.2% |
| Grant | $15,000 | 3 | 0.1% |
| Charitable Contribution | $100.00 | 1 | 0.0% |
Payments by Type
General
$9.5M
105,663 transactions
Research
$6.1M
987 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | $3.1M | 0 | 433 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | $994,507 | 2 | 129 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | $795,195 | 0 | 132 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | $463,033 | 0 | 182 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | $237,483 | 0 | 53 |
| Investigator Sponsored Study (IIS) | $103,669 | 0 | 7 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | $96,127 | 1 | 22 |
| A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adults with Bilateral Nasal Polyps using Nasoendoscopic Video OPN-FLU-NP-3104 | $95,419 | 0 | 10 |
| CS-2201 Study | $66,993 | 0 | 8 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps | $15,791 | 0 | 4 |
| A 24-Week Randomized,Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal administration of 186 and 372 microgram of OPN-375 BID in Subjects with CS with or without the presence of Nasal Polyps ONP-FLU-CS-3205 | $14,323 | 0 | 1 |
| A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase OPN-FLU-NP-3103 | $11,250 | 0 | 4 |
| CS2201 | $10,549 | 1 | 1 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps | $3,500 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Naveen Bhandarkar, M.d, M.D | Otolaryngology | Orange, CA | $453,011 | $0 |
| Dr. Joseph Han, Md, MD | Otolaryngology | Norfolk, VA | $333,504 | $0 |
| Jeffrey Bedrosian, Md, MD | Otolaryngology | Portland, ME | $263,798 | $0 |
| James Palmer, Md, MD | Otolaryngology | Philadelphia, PA | $230,817 | $0 |
| Dr. Mark Mehle, Md, MD | Otolaryngology | Cleveland, OH | $201,010 | $0 |
| Eric Karlin, M.d, M.D | Allergy & Immunology | Williamsburg, VA | $175,726 | $0 |
| Kevin Mclaughlin, M.d, M.D | Otolaryngology | Covington, LA | $158,725 | $0 |
| Mr. Nathanael Brady, D.o, D.O | Allergy & Immunology | Colorado Springs, CO | $143,940 | $0 |
| Unknown Provider | — | — | $140,047 | $0 |
| Dareen Siri, M.d, M.D | Allergy & Immunology | Normal, IL | $114,021 | $0 |
| Randall Ow | Otolaryngology | Roseville, CA | $112,636 | $0 |
| Dr. John Schneider, Md, MD | Otolaryngology | Saint Louis, MO | $102,472 | $0 |
| Dr. Douglas Reh, M.d, M.D | Otolaryngology | Lutherville Timonium, MD | $92,940 | $0 |
| Dr. Roheen Raithatha, M.d, M.D | Facial Plastic Surgery | New York, NY | $89,670 | $0 |
| Sally Bailey, Md, MD | Allergy | Baltimore, MD | $88,017 | $0 |
| William Yao, M.d, M.D | Otolaryngology | Houston, TX | $83,125 | $0 |
| Maeve O'connor, Md, MD | Allergy & Immunology | Charlotte, NC | $82,853 | $0 |
| Subinoy Das, Md, MD | Otolaryngology | Columbus, OH | $81,183 | $0 |
| Dr. Kent Lam, M.d, M.D | Otolaryngology | Norfolk, VA | $74,975 | $0 |
| Thomas Higgins, Md, MD | Otolaryngology | Louisville, KY | $73,131 | $0 |
| Dr. Eric Schenkel, Md, MD | Allergy & Immunology | Bethlehem, PA | $72,074 | $0 |
| Bruce Prenner, Md, MD | Allergy & Immunology | San Diego, CA | $66,459 | $0 |
| Dr. Iftikhar Hussain, Md, MD | Allergy & Immunology | Tulsa, OK | $64,251 | $0 |
| Dr. Vinay Mehta, M.d, M.D | Allergy & Immunology | Laguna Niguel, CA | $63,589 | $0 |
| Mr. Thomas Murphy, Md, MD | Allergy & Immunology | Charleston, SC | $62,147 | $0 |
About Optinose US, Inc.
Optinose US, Inc. has made $15.6M in payments to 14,798 healthcare providers, recorded across 106,650 transactions in the CMS Open Payments database. In 2024, the company paid $1.4M. The top product by payment volume is Xhance ($9.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Otolaryngology ($3.9M to 3,210 doctors).
Payment categories include: Food & Beverage ($2.2M), Consulting ($1.6M), Research ($6.1M), Travel & Lodging ($819,514).
Optinose US, Inc. is associated with 2 products in the CMS Open Payments database.